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ObjectiveaaWe have carried out a bibliometric study on the scientific publications in relation to atypical or second-generation antipsy-
chotic drugs (SGAs) in South Korea.
MethodsaaWith the EMBASE and MEDLINE databases, we selected those publications made in South Korea whose title included the 
descriptors atypic* (atypical*) antipsychotic*, second-generation antipsychotic*, clozapine, risperidone, olanzapine, ziprasidone, que-
tiapine, sertindole, aripiprazole, paliperidone, amisulpride, zotepine, asenapine, iloperidone, lurasidone, perospirone and blonanserin. 
We applied some bibliometric indicators of paper production and dispersion with Price’s law and Bradford’s law, respectively. We also 
calculated the participation index (PI) of the different countries, and correlated the bibliometric data with some social and health data 
from Korea (such as total per capita expenditure on health and gross domestic expenditure on research and development).
ResultsaaWe collected 326 original papers published between 1993 and 2011. Our results state fulfilment of fulfilled Price’s law, with 
scientific production on SGAs showing exponential growth (correlation coefficient r=0.8978, as against an r=0.8149 after linear adjust-
ment). The most widely studied drugs were risperidone (91 papers), aripiprazole (77), olanzapine (53), and clozapine (43). Division into 
Bradford zones yielded a nucleus occupied by the Progress in Neuro-Psychopharmacology and Biological Psychiatry (36 articles). A to-
tal of 86 different journals were published, with 4 of the first 10 used journals having an impact factor being greater than 4.
ConclusionaaThe publications on SGAs in South Korea have undergone exponential growth over the studied period, without evidence 
of reaching a saturation point. Psychiatry Investig 2013;10:8-16
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INTRODUCTION
The main therapeutic pillar for schizophrenia during the 
last 60 years have been antipsychotic drugs. The so-called 
“psychopharmacological revolution” in the context of treating 
schizophrenic patients, began in the 1950s with the clinical 
introduction of chlorpromazine1,2 and haloperidol.3 
These first drugs, called first-generation, classical or typical, 
biochemically characterized for blocking dopamine receptors, 
showed a great efficacy at reducing schizophrenia positive 
symptoms (hallucinations, delusion, etc.). But their main lim-
itation is side effects, principally extrapyramidal symptoms 
(EPS). But after the reintroduction in the United States of clo-
zapine, an antipsychotic drug commercialized in the 1960s, 
later withdrawn due to inducing agranulocytosis,4 the re-
search expectations changed dramatically. Apart from causing 
few EPS, this agent showed efficacy in both positive and nega-
tive symptoms of schizophrenia as well as in patients who are 
refractory to other antipsychotic treatment.5 Also, this drug 
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had differential pharmacological characteristics, especially at 
the level of the receptor blockage. Clozapine was the third cor-
nerstone on the history of antipsychotic pharmacology, and 
opened the door to the so-called “atypical antipsychotics”6 or 
second-generation antipsychotic drugs (SGAs), with the in-
troduction of risperidone in 1993. 
As shown in Table 1, the advances achieved in the field of 
antipsychotic drugs in the past 20 years have been incredibly 
important, with the clinical introduction of numerous SGAs 
(risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, 
etc.). These agents have notably improved the quality of life of 
psychotic patients and have contributed decisively to weaken-
ing the stigmatization that has traditionally accompanied psy-
chiatric attention.7 With the clinical introduction of the new 
SGAs since 1993 and, later on, with their licensing for treating 
bipolar disorder since 2003, research related to these drugs has 
advanced considerably, and this has undoubtedly translated 
into a considerable increase in the amount of scientific litera-
ture on these drugs-as it has been analyzed, in the specific case 
of Korea, in this study.
South Korea, once one of the four little Asian dragons, is 
now one of the great 20-50-class economic powers of East 
Asia, and is the most industrialised member country of the 
Organization for Economic and Co-operative Development 
(OECD). As of March 2011, South Korea (population of 50 
million) has 3,122 board-certified psychiatrists (and 621 resi-
dent psychiatrists), 84 training hospitals, 171 mental hospitals 
(382 hospitals if including general hospitals that has psychia-
try department), 861 private outpatient clinics, and 1.5 psy-
chiatric outpatient clinics per 100,000 population.8
The number of psychiatric beds in Korea has continuously 
increased from the 1980s and this rate of increase is higher 
than in any other OECD member nation.9 The patients ad-
mitted to mental hospitals belong primarily to the diagnostic 
of schizophrenia (67%).10 But it is problematic that patients 
with schizophrenia are still predominantly treated by hospi-
talization in Korea, and mean length of stay is greater than in 
other countries. The infrastructure to support the implemen-
tation of the mental health policy has yet to be strengthened.11
The use of bibliometric indicators for studying research ac-
tivity in a specific country in a particular field is based on the 
premise that scientific publication is the essential result of 
such activity.12 Bibliometric studies are useful tools for assess-
ing the social and scientific relevance of a given discipline or 
field.13 Our group has studied, with a bibliometric approach, 
the evolution of scientific literature in psychiatry by specific 
research groups, on different psychiatric disorders, on aspects 
related to the discipline, and on specific therapeutic tools in 
the field of psychopharmacology.14-19 Here, we specifically car-




The databases used in this bibliometric study were MED-
LINE (Index Medicus, U.S. National Library of Medicine, 
Bethesda, MD, United States) and Excerpta Medica (Elsevier 
Science Publishers, Amsterdam, Netherlands), which are 
considered the most exhaustive databases in the biomedical 
field, and which both participate in EMBASE Biomedical An-
swer web (Elsevier B.V.).
With remote downloading techniques, we selected papers 
containing, in the author address (AD) section the descriptor 
South Korea, and in the TI (title) section, the descriptors 
atypic* (atypical*) antipsychotic*, second-generation antipsy-
chotic*, clozapine, risperidone, olanzapine, ziprasidone, que-
tiapine, sertindole, aripiprazole, paliperidone, amisulpride, 
zotepine, asenapine, iloperidone, lurasidone, perospirone and 
blonanserin, published in the period from 1993 to 2011. The 
rest of the descriptors, referring to pharmacological aspects, 
Table 1. Clinical development of second generation antipsychotics
Company Launch
Clozapine Wander Laboratories 1972* Switzerland
Zotepine Fujisawa 1982† Japan
Amisulpride Synthelabo 1986 Portugal
Risperidone Johnson & Johnson 1993 UK/Canada
Sertindole Abbott Laboratories 1996‡ UK
Olanzapine Eli Lilly 1996 USA/UK
Quetiapine AstraZeneca 1997 USA/UK
Ziprasidone Pfizer 2001 USA
Perospirone Dainippon Sumitomo  
  Pharma
2001 Japan
Aripiprazole Otsuka/Bristol-Myers  
  Squibb
2002 USA
Paliperidone Janssen Pharmaceutica 2007 USA
Blonanserin Dainippon Sumitomo  
  Pharma
2008 Japan
Asenapine Schering-Plough 2009 USA
Iloperidone Novartis AG 2009 USA
Lurasidone Dainippon Sumitomo  
  Pharma
2011 USA
*reintroduced in 1990 in USA and UK after being withdrawn 
from the market in 1975, †commercialized by Astellas in Germany 
in 1990, ‡marketing authorization was suspended by the European 
Medicines Agency (EMA) in 1998 and the drug was withdrawn 
from the market. In 2002, based on new data, the EMA suggested 
that sertindole could be reintroduced for restricted use, and with 
extensive ECG monitoring requirement
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were not restricted to any field of the database. For the pur-
poses of this study we considered all original articles, brief ar-
ticles, reviews, editorials, letters-to-the editor, etc., and all du-
plicated papers were omitted. In this regard, the database 
used permits the elimination of items that may be duplicated 
in each of the databases (MEDLINE and EMBASE).
With manual coding after studying the title and/or abstracts 
of the articles, we divided those papers into four groups: “ex-
perimental pharmacology,” “clinical efficacy,” “tolerance and/
or safety,” and “not specified group.” 
Bibliometric indicators
Among the bibliometric indicators of production applied is 
Price’s law.20 This law is the indicator most widely used in ana-
lysing the productivity of a specific discipline or a particular 
country, to reflect a fundamental aspect of scientific produc-
tion, which is its exponential growth. To assess whether the 
growth of scientific production in SGAs follows Price’s law of 
exponential growth, we made a linear adjustment of the data 
obtained, according to the equation y=3.517χ-17.991, and an-
other adjustment to an exponential curve, according to the 
equation y=0.089e0.3701χ.
As a bibliometric indicator of the dispersion of scientific in-
formation, we used Bradford’s law.21 With the aim of revealing 
the distribution of the scientific literature in a particular disci-
pline, Bradford proposed a model of concentric zones of pro-
ductivity (Bradford zones) with decreasing density of infor-
mation.21 Thus, each zone would contain a similar number of 
papers, but the number of journals in which these are pub-
lished would increase on passing from one zone to another. 
This model permits identification of the journals most widely 
used or with greatest weight in a given field of scientific pro-
duction. 
We used the impact factor (IF)22 as an indicator of the pub-
lications’ repercussion. This indicator, developed by the Insti-
tute for Scientific Information (Philadelphia, Pennsylvania, 
USA), is published annually in the Journal Citation Reports 
(JCR) section of the Science Citation Index (SCI). The IF of a 
journal is calculated on the basis of the number of times this 
journals is cited in the source journals of the SCI during the 
two previous years and the total number of articles published 
by the journal in question in these two years. The JCR lists 
scientific journals by specific areas, ascribing to each of them 
their corresponding IF and establishing a ranking of “pres-
tige.”22 We used the IF data of 2010 published in the JCR of 
2011.
Another indicator included in the present analysis is the 
national participation index (PI) of Korea for overall scientific 
production (the ratio of the number of papers generated by 
South Korea and the total number of papers on this topic). 
This PI has also been compared with global PI in biomedical 
and health sciences (as well as for Psychiatry and Neurology 
area in particular). Likewise, the PI has been correlated with 
some health data, such as total per capita expenditure on he-
alth and gross domestic expenditure on research and develop-
ment (R&D). The PI has also been correlated with the corre-
sponding PI for the world’s 10 most productive countries dur-
ing the period from 1993 to 2011. Its health data were obtai-
ned from the OECD Health Division,23 and WHO Depart-
ment of Health Statistics and Informatics.24
RESULTS
After study of the analysed database, during the period from 
1993 to 2011, we obtained 326 original papers (articles, re-
views, editorials, letters-to-the-editor, etc.) dealing with dif-
ferent aspects related to SGAs in South Korea. Of these, 91 
papers correspond to risperidone, 77 to aripiprazole, 53 to 
olanzapine, 43 to clozapine, 34 to quetiapine, 18 to ziprasi-
done, 14 to amisulpride, 12 to paliperidone, 3 to sertindole 2 
to blonanserin, and 2 to lurasidone. We did not find any pa-
per on zotepine, asenapine, iloperidone and perospirone was 
found. Perospirone is not available in Korea.
As illustrated in Figure 1, over the last 20 years there has 
been a marked increase in the number of SGA publications 
generated in South Korea on a worldwide basis. As shown in 
Figure 1, the mathematical adjustment to an exponential cur-
ve permitted us to obtain a correlation coefficient r=0.8978, 
indicating 19.39% of variance unexplained by this fitting. In 
contrast, the linear adjustment of the measured values pro-
vides an r=0.8149, and therefore a percentage of unexplained 
Figure 1. Growth of scientific production on second-generation an-
tipsychotic drugs in Korea. A linear adjustment of the data was car-
ried out, and a fitting to an exponential curve for SGA papers ac-
cording to Price’s law20 was found. Linear adjustment: y=3.517χ- 
17.991 (r2=0.6641). Exponential adjustment: y=0.089e0.3701χ (r2= 
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variance of 33.59%. With these data, we can conclude that the 
database analyzed was more in keeping with an exponential 
fitting than a linear one, and that the postulates of Price’s law 
were fulfilled. 
The clinical introduction of the new SGAs in different coun-
tries of the world, together with their licensing for treating bi-
polar disorder, is to have contributed substantially to the in-
crease in scientific production in the SGA field in Korea, as 
can be seen in Figure 2. Further, Figure 3 depicts the evolu-
tion that has occurred in the last two decades of all SGA pa-
pers. With effects from 2004 and 2008, the growth was mainly 
due to two drugs, risperidone and aripiprazole, respectively. 
Figure 4 illustrates the matter even better, by showing that cu-
mulative growth in total SGA scientific production in Korea 
was increased in each five-year period compared to the previ-
ous one with even gradual increment. This growth was always 
higher (in the three consecutive five-year periods) compared 
to the global growth of Korean science in biomedicine and 
health, and to the specific field of Psychiatry and Neurology. 
As regards to the scientific journals in which the SGA pa-
pers had been published, we applied the Bradford’s model. 
The mean number of articles per Bradford zone was 47.79, 
though if we discarded the last zone, whose accuracy was ob-
viously lower, the mean would be 51.46. Table 2 shows the di-
vision into Bradford’s areas of the papers in this study. The 
nucleus or first zone would be made up exclusively of the 
Progress in Neuro-Psychopharmacology and Biological Psy-
chiatry, with 36 papers, and the second zone European Neu-
ropsychopharmacology (n=35). The rest of the journals ana-
lyzed are included in zones 3 to 9. A total of 86 different jour-
nals were used to publish those papers analysed. To note, the 
10 most used journals accounted for 53.37% of all papers in 
Figure 4. Cumulative growth by five-year periods of scientific pro-
duction on total productivity in biomedicine and health sciences, 
Psychiatry and Neurology area, and second-generation antipsy-
chotic drugs in Korea. Data from each five-year period refer to evo-
lution over the previous period. The period of reference is 1992-96. 
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2 1 35 1
3 2 39 2
4 3 35 1.5
5 4 37 1.33
6 6 38 1.5
7 12 37 2
8 24 36 2
9 33 33
Total number of journals=86, Average number of articles=36.22, 
Average number of articles, excluding the last Bradford zone=36.62
Figure 2. Number of documents on second-generation antipsy-
















































































Figure 3. Evolution of scientific papers on five most relevant sec-
ond-generation antipsychotic drugs (based on MEDLINE and EM-
BASE from 1999 to 2011).
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this study. 
Table 3 shows these 10 journals most used for the diffusion 
of scientific SGA papers by Korean authors and their corre-
sponding IFs, according to the JCR of 2010, and the PI of the 
journals on total database in the analyzed period. The jour-
nals (Table 3) most extensively used for the diffusion of SGA 
papers have high IFs (6 of them having an IF being greater 
than 2, and 4 an IF being greater than 4). 
Manually classifying articles, we found that 54.61% of them 
belonged to the “clinical efficacy” group, 24.54% to the “toler-
ance and safety” group, 16.87% to the “experimental pharma-
cology” group, and 3.98% to the “not specified” group (main-
ly, pharmacoeconomic analysis and articles of prescribing 
patterns). Clinical studies are mainly devoted to schizophre-
nia (n=87) and bipolar disorder (n=40), and to a lesser extent, 
to depressive disorders (n=12) and dementia (n=8).
The general contribution of Korean science, within this the-
matic area, represents a global PI of 1.61 with respect to world 
production in period analyzed. Table 4 shows that among the 
countries generating most significant SGA research, the USA 
(whose PI is 31.84), is most significant, followed by the Unit-
ed Kingdom (PI=7.97), Germany (PI=6.33), Canada (PI= 
5.68), Italy (PI=4.59) and Spain (PI=3.93). 
If we consider the paper productivity of these countries in 
the field of Psychiatry and Neurology, only 2 (Spain and Can-
ada) of the 10 largest producers in biomedicine and health 
sciences (in the period of 1993-2011), and South Korea devot-
ed a higher percentage of attention to the SGA study (Figure 
5). In the analysis of the correlation between PI and the per 
capita health expenditure of each of the countries with the 
highest scientific production in health sciences, the distribu-
Table 3. The 10 journals with highest number of publications on second-generation antipsychotic drugs from Korea
Journal Nº documents PI IF*
Progress in Neuro-Psychopharmacology and Biological Psychiatry 36 11.04 2.877
European Neuropsychopharmacology 35 10.74 4.201
Human Psychopharmacology Clinical and Experimental 20 6.13 2.607
International Journal of Neuropsychopharmacology 19 5.83 4.699
Clinical Psychopharmacology and Neuroscience 12 3.68 -
Journal of Cancer Education 12 3.68 0.682
Journal of Clinical Psychopharmacology 11 3.37 4.857
Psychiatry Investigation 10 3.07 0.221
Journal of Clinical Psychiatry 10 3.07 5.023
Psychiatry and Clinical Neurosciences 9 2.76 1.559
*Journal Citation Report, 2010 (JCR, 2011). PI: participation index, IF: impact factor 2010
Table 4. Distribution of documents on SGAs in the world’s 10 most 
productive countries in biomedicine and health sciences and South 







1 USA 25.78 35.61 31.84 1.14
2 UK 7.36 9.92 7.97 1.01
3 Japan 6.62 6.82 3.27 0.61
4 Germany 6.30 7.93 6.33 1.02
5 France 4.55 4.93 3.46 0.89
6 China 3.95 2.90 2.00 0.88
7 Italy 3.87 4.76 4.59 1.23
8 Canada 3.67 5.03 5.68 1.44
9 Spain 2.69 2.90 3.93 1.73
10 Australia 2.47 3.07 2.69 1.12
South Korea 1.31 1.17 1.61 1.90
*the world’s 10 most productive countries in biomedicine and 
health sciences (and South Korea) for the period  of 1993-2011, 
†their productivity in the discipline of Psychiatry and Neurology; 
Total documents 1993-2011: 13,746,667; Total documents in Neu-
rology & Psychiatry Area 1993-2011:1,471,156. Psy-Neurol: area of 
focus in Neurology and Psychiatry, SGAs: second-generation anti-
psychotic drugs
Figure 5. Relationship between production of scientific literature on 
SGAs and total production in the field of Psychiatry and Neurology 
in the world’s 10 most productive countries in biomedicine and heal-
th sciences and South Korea. PI: participation index, SGAs: sec-
ond-generation antipsychotic drugs.
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tion obtained was quite similar, except for China (Figure 6), 
although in this case it is an artifact due to the small Chinese 
per capita health expenditure (265 purchasing power parity 
Int $).
Table 5 shows the most Korean productive institutions to 
produce SGA papers in this study. As it can be seen, 24.54% of 
total production was generated in Seoul National University 
Bundang Hospital, and St. Marys Hospital at The Catholic 
University of Korea College of Medicine. But the rankings here 
are solely based on the information given in the AD field in 
the EMBASE Biomedical Answer web database, i.e., we iden-
tified affiliated institutions of the author address of those SGA 
papers in this study.
DISCUSSION
Bibliometric studies constitute interesting tools for assess-
ing the social and scientific importance of a given discipline 
over a specific time period. The term “bibliometrics” was in-
troduced in 1969 by Alan Pritchard, to define the application 
of mathematical and statistical methods to the process of dis-
semination of written communication in the area of scientific 
disciplines, by means of quantitative analysis of the different 
aspects of this type of communication.25 These analyses per-
mit an overview of the growth, size and distribution of the 
scientific literature related to a particular discipline, and the 
study of the evolution of not only the biomedical specialty, 
field of specialization or issue in question, but also the scien-
tific production of an institution, country, author or research 
group.12 The utility of bibliometric analysis is obvious. It en-
ables to monitor and to map the state of the art in researchers’ 
respective fields, to trace and to track group or individual or 
scientific performance, and to back up the justification of re-
search funding allocations, etc.
Taking into account these premises, the design of the pres-
ent analysis allows us to make a global assessment of the gr-
owth of scientific literature in relation to SGAs in South Korea. 
In this regard, it should be stressed how the number of scien-
tific publications has undergone exponential growth over the 
last 20 years, and especially after 2007, without evidence, up 
to the end of the period studied, of the process of saturation 
postulated by Price in his theory of expansion of scientific lit-
erature.20 These bibliometric data show a close correlation with 
the prescription data in this region (China, Hong Kong, Ja-
pan, Korea, Singapore and Taiwan), as revealed in the phar-
macoepidemiological study of the Research on Asian Psycho-
tropic Prescription (REAP) Project. The prescribing patterns 
in 2001, 2004 and 2008 showed a significant increase of the 
uses of SGAs (2001; 45.5%, 2004; 64.7%, 2008; 76.6%).26,27
Precisely, the great development of the scientific literature 
on SGAs coincides with its approval for marketing by the US 
Table 5. Contribution of SGA papers from different institutions in 
Korea
Institution N
Seoul National University Bundang Hospital,  
  Chongrogu, Seoul
45
St. Marys Hospital, Catholic University of Korea College  
  of Medicine, Bucheon
35
Chonnam National University Hospital, Gwangju 22
Korea University College of Medicine, Seongbuk-gu, Seoul 22
Catholic University of Korea, College of Medicine, Seoul 20
Inje University, College of Medicine, Goyang 20
University of Ulsan College of Medicine, Asan Medical  
  Center, Seoul
12
Ansan Hospital, Korea University, Ansan, Kyunggi 12
Naju National Hospital, Naju-si, Jeollanam-do 9
Sungkyunkwan University School of Medicine, Jangan-gu,  
  Suwon, Gyeonggi-do
8
Anam Hospital, Korea University College of Medicine,  
  Seongbuk-gu, Seoul
8
SGA: second-generation antipsychotic drug, n: number of docu-
ments in the study database
Figure 6. Per capita health expenditure and relationship between 
production of scientific literature on SGAs and per capita health ex-
penditure and gross domestic expenditure on R&D, in the world’s 
10 most productive countries in biomedicine and health sciences 
and South Korea. SGAs: second-generation antipsychotic drugs, 
R&D: research and development, PI: participation index, PPP: pur-
chasing power parity. Total health expenditure per capita PPP US 
$ (data from the Organization for Economic and Co-operative De-
velopment [OECD] 2009).23 Japan and Australia; Data 2008; China: 
Total health expenditure per capita PPP Int $ (data 2008).24; Gross 
domestic expenditure on R&D (%): Data OECD 2010, except USA 
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Food and Drug Administration (FDA) and other internatio-
nal regulatory agencies in the treatment bipolar disorder. Sin-
ce 2004, other SGAs such as risperidone, quetiapine, ziprasi-
done, aripiprazole, and asenapine, etc. have been also app-
roved for the treatment of manic episodes, and olanzapine and 
aripiprazole for relapse prevention in patients with bipolar dis-
order.28 Quetiapine is indicated as monotherapy for the acute 
treatment of depressive episodes associated with bipolar dis-
order, and olanzapine-fluoxetine combination for treating 
treatment-resistant major depressive disorder.28 Also aripipra-
zole was approved in 2007 by the FDA for treating treatment-
resistant major depression as an add-on to an antidepressant.28 
Likewise, with increasing multiple indications of SGAs, there 
have been also a steep growth of clinical trials using SGAs for 
various psychiatric disorders in Korea, currently about 100 
clinical trials has been finished or actively recruiting patients 
based on the ClinicalTrial.gov database (http://clinicaltrials.
gov). Finally, SGAs are also commonly used (and studied) in 
numerous off-label indications, such as toxic psychosis, agita-
tion symptoms, tics, substance abuse disorders, etc.29,30 In this 
sense, there has been an important upsurge in the five-year 
period of 2002-06, coinciding with the period of official ap-
proval of the new SGAs and new indications for SGAs (bipo-
lar disorder, depression, autism, etc.). In the individual analysis 
of the new SGAs, risperidone emerges as the agent most wide-
ly studied. But it is striking to note the increase in publications 
on clozapine since 2007 with the increase in the clinical use of 
this antipsychotic detected in Korea by the REAP project.31
Another aspect of interest in relation to scientific produc-
tion that we analyzed is its quality of papers from Korea. To 
this end, we used the indicators of impact and excellence of 
the publications on the topic in question. The fact that such 
prestigious journals as Journal of Clinical Psychiatry (IF= 
5.023), Journal of Clinical Psychopharmacology (IF=4.857), 
International Journal of Neuropsychopharmacology (IF= 
4.699), or European Neuropsychopharmacology (IF=4.201) 
published articles on SGAs from Korea is an important factor, 
indicating the relevance (both clinical and social) that this 
country has acquired in recent years. To note, among the 10 
publications most widely used in Korea for the international 
divulgation on SGAs research, 6 journals are in the ranking of 
the most relevant in the field of Psychiatry (IF in 2010 being 
greater than 2).
Although some mid-2000s’ studies suggested that only 1% 
of all scientific publications on Korea were mental health,9 our 
results confirm that during the period of 1993-2011, the per-
centage of papers in the area of Psychiatry and Neurology ac-
counted for 9.55% of the total scientific production in Korea. 
As we have shown in recent studies,19 scientific research on 
SGAs is one of the fastest growing fields within the field of 
psychiatry. Similarly, some authors, also applying bibliometric 
tools, have reported the research activity in the field of schizo-
phrenia as superior to that of other fields of psychiatry.32 These 
authors also suggest that the attraction of research on schizo-
phrenia may have been positively affected by the clinical per-
ception of the greater seriousness of the illness compared to 
other psychiatric pathologies. Moreover, Theander and Wet-
terberg report that the number of references on schizophrenia 
in MEDLINE has followed the general increase of medical 
publications, which accounts for 0.42% compared to the total 
medical literature in the period studied.33
The two major English-speaking countries, USA and UK, 
head the ranking of producer countries, and between them 
generate over a third of total scientific production in this field 
(39.81%). The fact that in these two countries are home to the 
pharmaceutical companies responsible for the development of 
SGAs (olanzapine - Eli Lilly, USA; risperidone and paliperi-
done - Janssen Pharmaceutica, USA; quetiapine - AstraZene-
ca, UK; ziprasidone - Pfizer, USA; and aripiprazole - Bristol-
Myers Squibb/Otsuka Pharmaceutical Co., USA/Japan) may 
help explain this high PI. 
Table 4 shows the data from the 10 most productive coun-
tries in biomedicine and health sciences and South Korea and 
compares the data for general productivity in the Psychiatry 
and Neurology discipline with productivity in the specific field 
of SGAs. It is worthy of note how some places, such as Spain, 
Canada, and South Korea sit near the top of the ranking for 
SGAs production (Figure 5), reflecting the special interest of 
these countries in research into these drugs. Other countries, 
such as the USA, Italy and Australia, maintain rates of pro-
ductivity in SGA research that are in proportion with their 
global index for psychiatry. Contrariwise, it is interesting to 
note the lower relative interest in these drugs, within the con-
text of their general production in psychiatry, of countries 
such as Japan, China, or France. 
The correlation of scientific production in SGAs with the 
per capita health expenditure of each country offers us a par-
allel view of this phenomenon; in general, there is confirma-
tion of the notion that the higher the spending on health, the 
greater the research production. In this regard, it should be 
made clear that a country’s scientific production in a given 
field tends to reflect a science research and development poli-
cy begun some years before the period analyzed, and is not 
the fruit of particular economic circumstances.16,17 It is strik-
ing, however, to observe the low ratios of countries such as 
Australia, South Korea or France. Despite being recently the 
world’s first 7 to meet the gross domestic product (GDP) per 
capita (PPP US$ 29,997), South Korea has a health expendi-
ture relatively low for developed countries (ranking 28; 6.9% 
of GDP). In addition, only 6% of health care expenditures by 
F López-Muñoz et al. 
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the government health department are devoted to mental he-
alth.11 The correlation analysis between scientific production 
in SGAs and the gross domestic expenditure on R&D located 
to Australia, Japan and Korea at the last three positions.
Limitations and strengths of the study
The readers are warned against over-interpreting the study 
findings because this study has three major limitations which 
are inherent to its bibliometric nature.34 
First, not all the SGA papers from South Korea were in-
cluded. This bibliometric study includes papers from EM-
BASE Biomedical Answer web. The criteria set by the data-
bases themselves determine the subsequent development of 
the studied materials.12,35 Excluded are those papers on SGAs 
if authors do not put the SGA descriptors in the titles or key 
words of the papers, national or local journals that are not in-
cluded in MEDLINE and Excerpta Medica, and those contri-
butions at scientific conferences and meetings.14 In fact, there 
are many Korean-based neuropsychopharmacological jour-
nals affiliated with psychiatric and neurological academic so-
cieties in Korea, such as the Journal of Korean Neuropsychi-
atric Association, the Korean Journal of Psychopharmacology, 
the Korean Journal of Biological Psychiatry, and the Korean 
Journal of Biological Therapies, etc. Hence, we have to keep in 
mind that more papers regarding experimental and/or clini-
cal papers of SGAs may exist in various neurosciences and 
clinical fields in Korea. In addition, Korea has English jour-
nals such as the Clinical Psychopharmacology and Neurosci-
ence which is affiliated with Korean College of Neurophar-
macology, which are not included in our search engines. 
Second, in the AD (author address) section the descriptor 
South Korea, we included only those papers with Korean cor-
responding authors in this study. By the research design, we 
did not count those papers as Korean papers if those Korean 
authors are not addressing authors of the papers. 
And third, the use of indicator impact factor to determine 
the merit or quality of scientific contributions is still debat-
able. The citation count may mean that the given topic is the 
study is “not yet mature” and is “in need of more studies.” But 
it may not mean the work is more important than those pa-
pers which do not get many citations. Differing in those in the 
Europe and Asia, American universities do not use impact 
factor as much to measure the production of a faculty mem-
ber.
Analyzing bibliometric information based on the propor-
tions of industry-sponsored, pre- and post-marketing trials/
reports, and independent clinical trials should also provide 
more detailed trend toward collaboration between academy 
and pharmaceuticals. 
In spite of the above-listed study limitations, bibliometric 
studies are useful in assessing the social and scientific rele-
vance of a given discipline or field.13 Those studies constitute 
an effective complement for the opinions and judgments of 
experts in each field, giving useful and objective tools to eval-
uate the results of scientific activity, offering a more realistic 
view of the picture and an indication of trends, as well as pre-
dicting how it might evolve.35 For future bibliometric research-
es, it should be useful to extend the analysis of research outputs 
to incorporate the impact of biomedical research on health-
care and policy decision-making. It suggests potential useful 
avenues for future bibliometric research - the media and in 
medical education. Covering bibliometric studies of research 
papers by clinical guidelines will give more practical informa-
tion to clinicians regarding real-world practice. More precise 
refinement of bibliometirc indicators should be further im-
proved as well. 
Conclusion
Keeping in mind of the above-listed limitations and stren-
gths, we have been able to offer a picture of the representa-
tiveness and evolution of international research on SGAs in 
Korea, observing the parameters of quality and dissemination 
most commonly employed at an international level. 
SGAs as a group of pharmaceutic class started to become 
number 1 in the market sale (US$ 14.6 billion per year) in 
2008 in the USA.28 Any new SGA, as a commercial commod-
ity, can easily become an instant “mega-drug” (by the defini-
tion of having the annual sale of US$ 500 million) if it can oc-
cupy only 4% of market share in the USA.28 Thus, research in 
this field will definitely continue to grow in the coming years. 
We need to bear in mind that the ideal antipsychotic drug has 
not yet been found,7 and that the need of treating many treat-
ment-resistant patients is waiting to be met.36
Besides, SGAs have, and will continue to have, an ever-ex-
panding range of clinical indications, both within the psychi-
atric ambit and outside it, to judge from the promising results 
obtained for the different pathologies with which they have 
been studied;29 in consequence, scientific production in rela-
tion to these drugs will certainly continue to be abundant, as 
is happening with the prescription patterns of SGA in this re-
gion.
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